Enhanced CAR T-cell therapy shows early promise for B-cell cancers in first-in-human trial

October 18, 2026
10:12 pm

Results from a Phase I clinical trial led by The Ohio State University Comprehensive Cancer Center—Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC—James) show a possible way to improve therapy options for patients with relapsed or treatment-resistant B-cell blood cancers. The findings are published in Blood Cancer Discovery.

Researchers were able to build on earlier work done at Ohio State that used CAR T-cell therapy to enhance treatment of B-cell blood cancers. About half of all blood cancers are B-cell blood cancers, including lymphoma and some leukemias.

This trial tested CAR T-cell therapy targeting three proteins—CD19, CD20 and CD22—and used a different protein called OX40 to boost immune response in patients.

Enhanced CAR T-cell therapy shows early promise for B-cell cancers in first-in-human trial

Sign up for Blog Updates